Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.
- Securities for sale: 29,432 common shares.
- Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
- Proposed sale date: 08 / 04 / 2025 on NASDAQ.
- Aggregate market value of planned sale: $61,589.40.
- Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
- Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.
No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR’s capital structure.